Genmab's shares double in three months after a string of cancer drug trial wins

Summary

According to CNBC, the shares of Genmab, a little-known biotech company, have doubled in three months following a string of cancer drug trial wins. The report says the gains strengthen the company's push to own more of the medicines it develops.

Timeline

1. CNBC

   3 Nov 2026, 09:35 UTCSource ↗

   CNBC reports that Genmab's shares have doubled in three months after a string of cancer drug trial wins, which strengthens the company's push to own more of the medicines it develops.